Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(para-glutaramidophenyl-ethyl)-piperidinium-N‑oxide is a synthetic small molecule classified as an anilide and a piperidine N‑oxide derivative. It is functionally related to glutaric acid and contains benzene and oxidopiperidine moieties. This compound has been used primarily as a transition state analogue hapten to elicit catalytic antibodies, specifically 5C8 and 14B9, in immunological research. Its main role is as an epitope for antibody generation rather than as a therapeutic agent. There are no approved medical indications or clinical trials for disease treatment involving this compound[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(para-glutaramidophenyl-ethyl)-piperidinium-N-oxide.